Trial results

$ABOS — sabirnetug (ACU193)

Acumen Pharmaceuticals, Inc. (ABOS) sabirnetug (ACU193): trial results in Alzheimer's disease, 2026.

Research by Catalyst Intel

The catalyst

"ALTITUDE-AD topline results expected in late 2026, inclusive of efficacy, safety and biomarker data"

— Acumen Pharmaceuticals, 8-K filed 2026-09-16 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ABOS-SABIRNETUGAC-2026

Company

Acumen Pharmaceuticals, Inc.

Kind

Trial results

Indication

Alzheimer's disease

Window

2026-09-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.